Table 2. Stage 1 and 2 patients without MYCNA. Characteristics at diagnosis.

	Stage
	1 (n=288)			2 (n=123)
Characteristics	No. of patients	%	95% CI	No. of patients	%	95% CI	P-value
Gender
Male	167	58	52.3–63.7	61	49.6	40.8–58.4	0.11
Female	121	42	36.3–47.7	62	50.4	41.6–59.2
M/F ratio		1.4			1
Age (months)							0.63
Median		11		11
0–17	185	64.2	58.7–69.8	76	61.8	53.2–70.4
>18	103	35.8	30.2–41.3	47	38.2	29.6–46.8
Site of primary tumour							<0.0025
Neck	14	4.9	2.4–7.3	7	5.7	2.3–11.4
Thorax	65	22.5	17.7–27.4	43	35	26.5–43.4
Abdomen	197	68.4	63–73.8	61	49.6	40.8–58.4
Pelvis	12	4.2	1.9–6.5	12	9.7	4.5–15
Urine VMA (247 tested)							0.0008
Normal	118	67.4	60.5–74.4	32	44.4	33–55.9
Elevated	57	32.6	25.6–39.5	40	55.6	44.1–67
Urine HVA (231tested)							0.015
Normal	108	67.5	60.2–74.8	36	50.7	39.1–62.3
Elevated	52	32.5	25.2–39.8	35	49.3	37.7–60.9
Serum LDH (276 tested)							0.79
Normal	161	93.1	89.3–96.8	95	92.2	85.3–96.6
Elevated	12	6.9	3.1–10.7	8	7.8	3.4–14.7
Histopathologic category (320 tested)							<0.04
Favourable	191	88.4	84.2–92.7	83	79.8	72.1–87.5
Unfavourable	25	11.6	7.3–15.8	21	20.2	12.5–27.9
DNA index (216 tested)							0.72
Aneuploid	90	64.3	56.3–72.2	47	61.8	50.9–72.8
Di-tetraploid	50	35.7	27.8–43.6	29	38.2	27.2–49.1

HVA=homovanillic acid; LDH=lactate dehydrogenase; VMA=vanillylmandelic acid.